Recent advances in the management of pulmonary arterial hypertension [version 1; referees: 2 approved]

• Main Authors: Halley Tsai, Yon K. Sung, Vinicio de Jesus Perez
• Format: Article
• Language: English
• Published: F1000 Research Ltd 2016-11-01
• Series: F1000Research
• Subjects: Cardiovascular Pharmacology; Pharmacokinetics & Drug Delivery; Pulmonary Vascular Diseases; Vascular Diseases (Non-Coronary)
• Online Access: https://f1000research.com/articles/5-2755/v1

Over the past 20 years, there has been an explosion in the development of therapeutics to treat pulmonary arterial hypertension (PAH), a rare but life-threatening disorder associated with progressive elevation of pulmonary pressures and severe right heart failure. Recently, the field has seen the introduction of riociguat, a soluble guanylate cyclase stimulator, a new endothelin receptor antagonist (macitentan), and oral prostanoids (treprostinil and selexipag). Besides new drugs, there have been significant advances in defining the role of upfront combination therapy in treatment-naïve patients as well as proposed methods to deliver systemic prostanoids by use of implantable pumps. In this review, we will touch upon the most important developments in PAH therapeutics over the last three years and how these have changed the guidelines for the treatment of PAH. These exciting developments herald a new era in the treatment of PAH which will be punctuated by the use of more clinically relevant endpoints in clinical research trials and a novel treatment paradigm that may involve upfront double- or triple-combination therapy. We anticipate that the future will make use of these strategies to test the efficacy of upcoming new drugs that aspire to reduce disease progression and improve survival in patients afflicted with this devastating disease.